Research Topic

The Roles and Emerging Advances of Helicobacter pylori Eradication

About this Research Topic

Discovered in 1982, the bacterium Helicobacter pylori was regarded as a group I carcinogen by the International Agency for Research on Cancer (IARC) in 1994. Current consensus considers the microorganism a serious latent infectious disease, treated similar to tuberculosis and syphilis. The bacterium is ...

Discovered in 1982, the bacterium Helicobacter pylori was regarded as a group I carcinogen by the International Agency for Research on Cancer (IARC) in 1994. Current consensus considers the microorganism a serious latent infectious disease, treated similar to tuberculosis and syphilis. The bacterium is considered a crucial pathogen responsible for >80-90% of gastric adenocarcinoma. Evidence from cohort studies suggests that curing an H. pylori infection can prevent gastric cancer. Indeed, due to effective diagnosis and H. pylori treatment, gastric cancer went from ranking first in most common cancers in 1975, to the fifth most common today. However, the rapid increase in antibiotic resistance has significantly decreased the effectiveness of treatment. Unable to achieve expected results, conventional therapies are no longer as useful. As such a challenge has emerged, of interest to all clinicians.

New/alternative therapeutic agents or therapies are needed to increase chances for a higher cure rate. To explore these issues, this Research Topic will include both original papers and reviews related to: (1) new guidelines, treatment therapies, vaccines or major drugs for the management of an H. pylori infection; (2) use of natural resources such as herbal medicines and probiotics as supplements for more effective H. pylori treatment; (3) mechanisms of novel mutations in antibiotic resistance to provide the novel therapeutic targets and treatment options, (4) evidence from clinical trials to validate the effect of these new findings.

Since the resistance patterns and extents vary from country to country and region to region, we also welcome systematic and meta-analysis reviews about the global burden caused by H. pylori; the effects of different therapies; and global antibiotic resistance related to genotype patterns of mutations to unravel the overview of H. pylori-related consequences.


Keywords: Helicobacter pylori, Eradication Guidelines, Probiotics, Novel Mutation, Antibiotics Resistance


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Recent Articles

Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

20 November 2018 Manuscript
20 February 2019 Manuscript Extension

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

20 November 2018 Manuscript
20 February 2019 Manuscript Extension

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top
);